CoChat

A metabolite‐based machine learning approach to diagnose Alzheimer‐type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

Open access
Stamate, Daniel, Kim, Min, Proitsi, Petroula, Westwood, Sarah, Baird, Alison, Nevado‐Holgado, Alejo, Hye, Abdul, Bos, Isabelle, Vos, Stephanie J.B., Vandenberghe, Rik, Teunissen, Charlotte E., Kate, Mara Ten, Scheltens, Philip, Gabel, Silvy, Meersmans, Karen, Blin, Olivier, Richardson, Jill, De Roeck, Ellen, Engelborghs, Sebastiaan, Sleegers, Kristel, Bordet, Régis, Ramit, Lorena, Kettunen, Petronella, Tsolaki, Magda, Verhey, Frans, Alcolea, Daniel, Lléo, Alberto, Peyratout, Gwendoline, Tainta, Mikel, Johannsen, Peter, Freund‐Levi, Yvonne, Frölich, Lutz, Dobricic, Valerija, Frisoni, Giovanni B., Molinuevo, José L., Wallin, Anders, Popp, Julius, Martinez‐Lage, Pablo, Bertram, Lars, Blennow, Kaj, Zetterberg, Henrik, Streffer, Johannes, Visser, Pieter J., Lovestone, Simon, Legido‐Quigley, Cristina · 2019 · Alzheimer's & Dementia: Translational Research & Clinical Interventions
Cited by 132

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Introduction: Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in blood to categorize AD when compared to CSF biomarkers. Methods: This study analyzed samples from 242 cognitively normal (CN) people and 115 with AD‐type dementia utilizing plasma metabolites (n = 883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV). Results: On the test data, DL produced the AUC of 0.85 (0.80–0.89), XGBoost produced 0.88 (0.86–0.89) and RF produced 0.85 (0.83–0.87). By comparison, CSF measures of amyloid, p‐tau and t‐tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively. Discussion: This study showed that plasma metabolites have the potential to match the AUC of well‐established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trci.2019.11.001

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Stamate, D., Kim, M., Proitsi, P., Westwood, S., Baird, A., Nevado‐Holgado, A., Hye, A., Bos, I., Vos, S. J. B., Vandenberghe, R., Teunissen, C. E., Kate, M. T., Scheltens, P., Gabel, S., Meersmans, K., Blin, O., Richardson, J., De Roeck, E., Engelborghs, S., Sleegers, K., Bordet, R., Ramit, L., Kettunen, P., Tsolaki, M., Verhey, F., Alcolea, D., Lléo, A., Peyratout, G., Tainta, M., Johannsen, P., Freund‐Levi, Y., Frölich, L., Dobricic, V., Frisoni, G. B., Molinuevo, J. L., Wallin, A., Popp, J., Martinez‐Lage, P., Bertram, L., Blennow, K., Zetterberg, H., Streffer, J., Visser, P. J., Lovestone, S., & Legido‐Quigley, C.
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2019-01
Volume
5
Issue
1
Pages
933-938
ISSN
2352-8737 (ISSN-L)
OpenAlex
W2996431818
Cited by
132
References
5
FWCI
13.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.